This website uses cookies. By using the site you are agreeing to our Privacy Policy.

HOME >> Investor Relations >> Top Message >> Message Archive (October 28, 2016)


To Our Investors

I would like to express my sincere appreciation to all shareholders who support Japan Tissue Engineering (J-TEC). I will report below our most recent developments.

Approval of Additional Indication for Giant Nevus treatment

Autologous Cultured Epidermis

At the end of September 2016, J-TEC’s Autologous Cultured Epidermis, JACE, received a supplemental approval for the additional indication for “Giant Congenital Melanocytic Nevus (GCMN)” treatment from the Japanese Ministry of Health, Labour and Welfare (MHLW), the first case for a regenerative medicine in Japan. Given this approval, we now provide a new treatment option for patients with GCMN, which is designated as an orphan disease.

Road Towards Profitability

It has already been 4 months since I assumed the presidency here at J-TEC. In the 2nd quarter, we reduced the operating loss to less than half of that of the year-earlier period. We aim to generate profit in this FY2016, binding ourselves together with a common goal towards profitability. I very much appreciate your continuous support.

At J-TEC, we will also develop and expand new business as a Contract Development and Manufacturing Organization (CDMO). We will work together as one to become the true leading company in the field of regenerative medicine in Japan.

October 28, 2016
Aiichiro Hiruma
President & CEO
Japan Tissue Engineering Co., Ltd.